Group 1 - China Merchants Securities (Hong Kong) downgraded the rating of Giant Bio to neutral due to challenges such as a reputation crisis and a decline in sales during the Double Eleven shopping festival, indicating a potential strategic adjustment period in 2026 with no clear catalysts for rebound [1] Group 2 - CICC maintained a "outperform" rating for He Yu-B, setting a target price of 20 HKD, highlighting the approval of its first self-developed innovative drug, with an overall response rate (ORR) of 54%, which could provide new growth momentum for the company [2] Group 3 - CICC maintained a "outperform" rating for Mixue Group with a target price of 555 HKD, noting the brand's resilience in growth despite reduced delivery subsidies and the rapid expansion of its stores, indicating strong growth potential [3] Group 4 - CICC maintained a "outperform" rating for Tmall with a target price of 3.88 HKD, reporting that Q3 sales met expectations with healthy inventory and stable discounts, suggesting a potential stabilization in the channel [4] Group 5 - Huachuang Securities maintained a "strong buy" rating for Geely Automobile with a target price of 27.01 HKD, citing the completion of the Zeekr privatization significantly enhancing profits and brand synergy, with multiple flagship new models driving sales and average selling price (ASP) increases [5] Group 6 - Changjiang Securities maintained a "buy" rating for Aikang Medical, emphasizing its leading position in orthopedics and revenue surpassing pre-collection levels, with effective overseas expansion strategies [6] Group 7 - Changjiang Securities maintained a "buy" rating for Genscript Biotech, highlighting the establishment of a high-barrier pipeline in tumor vaccines and CAR-T therapies, with significant clinical trials expected to start soon [7] Group 8 - Shenwan Hongyuan maintained a "buy" rating for Tmall, noting improvements in channel efficiency and the end of a large-scale store closure phase, with a clear trend of recovery in the terminal market [8] Group 9 - Shenwan Hongyuan initiated coverage on China Railway with a "buy" rating, citing a substantial order backlog of 7.54 trillion, a high gross margin of 59.45% in its resource segment, and attractive valuation due to significant H-share discounts [9] Group 10 - Guosen Securities maintained an "outperform" rating for Zhongxin Innovation, reporting that the company's power battery installation volume ranked among the top three globally in October, with a year-on-year increase of over 75% in energy storage battery shipments [10]